Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals
Antiviral Therapy2008Vol. 14(7), pp. 1001–1004
Citations Over Time
Jasper van der Lugt, Joep M. A. Lange, Anchalee Avihingsanon, Jintanat Ananworanich, Siriporn Sealoo, David M. Burger, Meena Gorowara, Praphan Phanuphak, Kiat Ruxrungtham
Abstract
The generic lopinavir/ritonavir tablet showed C(min) plasma concentrations similar to what is described for the branded product, with good stability, independent of food intake. These data support the efforts in scaling up access to generic second-line treatment in middle- and low-income countries.
Related Papers
- → Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019(2020)39 cited
- → Gemfibrozil Concentrations Are Significantly Decreased in the Presence of Lopinavir-Ritonavir(2009)27 cited
- → Lopinavir/Ritonavir Pharmacokinetic Profile: Impact of Sex and Other Covariates Following a Change From Twice‐Daily to Once‐Daily Therapy(2007)17 cited
- PHARMACOKINETIC EXPOSURE AND VIROLOGIC RESPONSE IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH LOPINAVIR/RITONAVIR: AIDS CLINICAL TRIALS GROUP PROTOCOL A5153S: A SUBSTUDY TO A5150.(2015)
- → Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir(2012)3 cited